Boston Scientific gets preliminary FTC okay
This article was originally published in The Gray Sheet
Acquisition of ICD manufacturer Guidant moves closer to completion after Boston Scientific inked an agreement with Federal Trade Commission staff on April 5. The firm says the consent decree resolves all outstanding U.S. government antitrust issues but still requires final sign-off from FTC commissioners. On or around April 7, the firm will withdraw and re-file its antitrust notification with the agency, giving commissioners 30 days to review the details of the new agreement. Boston Scientific also is awaiting the completion of an antitrust review by the Eur-opean Commission, which will likely push final closing of the deal to mid-April (1"The Gray Sheet" April 3, 2006, p. 3)...
You may also be interested in...
European Commission (EC) antitrust regulators signed off, with some conditions, on Boston Scientific's acquisition of Guidant April 11, leaving U.S. clearance as the only remaining hurdle to closing the deal
Boston Scientific and Guidant shareholders approved the merger of their companies in separate votes March 31, leaving U.S. and European antitrust clearances as the only remaining hurdles to closing the deal
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.